Analysts Anticipate Bellicum Pharmaceuticals Inc (BLCM) Will Announce Quarterly Sales of $70,000.00
Equities analysts forecast that Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) will post $70,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Bellicum Pharmaceuticals’ earnings, with estimates ranging from $30,000.00 to $100,000.00. Bellicum Pharmaceuticals posted sales of -$70,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 200%. The business is scheduled to issue its next earnings results on Tuesday, March 12th.
According to Zacks, analysts expect that Bellicum Pharmaceuticals will report full-year sales of $910,000.00 for the current year, with estimates ranging from $600,000.00 to $1.20 million. For the next year, analysts forecast that the company will report sales of $5.65 million, with estimates ranging from $300,000.00 to $11.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.03. The business had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.07 million.
Shares of NASDAQ:BLCM opened at $4.04 on Friday. The firm has a market cap of $197.29 million, a P/E ratio of -1.42 and a beta of 1.10. The company has a quick ratio of 8.01, a current ratio of 8.01 and a debt-to-equity ratio of 0.39. Bellicum Pharmaceuticals has a 1-year low of $3.88 and a 1-year high of $10.26.
In other news, Director Jon P. Stonehouse acquired 10,000 shares of the business’s stock in a transaction on Friday, November 9th. The stock was bought at an average price of $4.56 per share, for a total transaction of $45,600.00. Following the transaction, the director now owns 10,000 shares in the company, valued at $45,600. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 9.84% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its position in Bellicum Pharmaceuticals by 8.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,874,395 shares of the biopharmaceutical company’s stock worth $23,866,000 after buying an additional 300,816 shares during the last quarter. BlackRock Inc. raised its position in Bellicum Pharmaceuticals by 10.2% during the 3rd quarter. BlackRock Inc. now owns 3,431,193 shares of the biopharmaceutical company’s stock worth $21,137,000 after buying an additional 318,799 shares during the last quarter. Vanguard Group Inc. raised its position in Bellicum Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,947,842 shares of the biopharmaceutical company’s stock worth $11,999,000 after buying an additional 23,410 shares during the last quarter. Frazier Management LLC purchased a new position in Bellicum Pharmaceuticals during the 2nd quarter worth $7,760,000. Finally, Wasatch Advisors Inc. raised its position in Bellicum Pharmaceuticals by 4.3% during the 3rd quarter. Wasatch Advisors Inc. now owns 963,148 shares of the biopharmaceutical company’s stock worth $5,933,000 after buying an additional 39,324 shares during the last quarter. Institutional investors own 56.13% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
See Also: What is a Tariff?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.